Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Holding LSTA?
Track your performance easily
LSTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.19 - $4.20
Previous CloseN/A
Volume45.87K
Average Volume (3M)43.61K
Market Cap
$31.23M
Enterprise Value-$10.97M
Total Cash (Recent Filing)$7.08M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Mar 27, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.51
Shares Outstanding8,394,903
10 Day Avg. Volume80,219
30 Day Avg. Volume43,607
Standard Deviation0.16
R-Squared0.14
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$15.00Price Target Upside304.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Lisata Therapeutics News
PremiumCompany Announcements
Lisata Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Lisata Therapeutics Reports Promising Q3 2024 Results
Options Prices
Currently, No data available
---
Ownership Overview
8.26% Insiders
2.87% Mutual Funds
3.55% Other Institutional Investors
82.99% Public Companies and
Individual Investors
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $2.19 and its highest was $4.20 in the past 12 months.
What is Lisata Therapeutics’s market cap?
Lisata Therapeutics’s market cap is $31.23M.
When is Lisata Therapeutics’s upcoming earnings report date?
Lisata Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 67 days.
How were Lisata Therapeutics’s earnings last quarter?
Lisata Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.75 by $0.16.
Is Lisata Therapeutics overvalued?
According to Wall Street analysts Lisata Therapeutics’s price is currently Undervalued.
Does Lisata Therapeutics pay dividends?
Lisata Therapeutics does not currently pay dividends.
What is Lisata Therapeutics’s EPS estimate?
Lisata Therapeutics’s EPS estimate is -0.76.
How many shares outstanding does Lisata Therapeutics have?
Lisata Therapeutics has 8,394,903 shares outstanding.
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Lisata Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.75. Following the earnings report the stock price went down -4.124%.
Which hedge fund is a major shareholder of Lisata Therapeutics?
Currently, no hedge funds are holding shares in LSTA
---
Lisata Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (304.31% Upside)
$15.00 (304.31% Upside)
Hedge Fund Trend
Decreased
By 50.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.19%
12-Months-Change
Fundamentals
Return on Equity
-47.87%
Trailing 12-Months
Asset Growth
-34.24%
Trailing 12-Months
Company Description
Lisata Therapeutics
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
---
LSTA Company Deck
---
LSTA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in reducing operating expenses and advancing clinical trials, particularly the ASCEND and BOLSTER trials. However, challenges remain with increased administrative costs, slower-than-expected trial enrollment, and continued net losses.Read More>---
LSTA Stock 12 Month Forecast
Average Price Target
$15.00
▲(304.31% Upside)
Technical Analysis
ESSA Pharma
―
Forte Biosciences
―
TuHURA Biosciences
―
Soleno Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering LSTA
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+23.25%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +23.25% per trade.
---